Looking forward to seeing you at World Vaccine Congress Europe 2024
Booth # 99
Sister companies APC and VLE Therapeutics (together known as the “Medicine Accelerator”) are thrilled to be attending the World Vaccine Congress 2024 from October 28th to 31st in Barcelona, Spain. This is the largest and most established European meeting on vaccine R&D, covering clinical development, bioprocessing & manufacturing, cancer immunotherapy and much more. It brings together R&D + Strategic Partnering for the Global Vaccine Industry from clinical development & immune profiling to vaccine safety and market access.
The Medicine Accelerator
The Medicine Accelerator is a 130,000 sq ft campus, the largest R&D site in the biopharma sector in Ireland and the expanded home for APC & VLE, will integrate the latest developments in scientific research, AI, neural networks and scientifically led manufacturing activities. This value chain is transforming medicine development and the time to patient for new and advanced therapeutics.
We partner with eight of the top 10 pharmaceutical companies globally. In addition to a wide range of biotech companies. APC & VLE work across any therapeutic areas. The group is currently working on 35+ medicines that transform patient treatment in areas such as oncology, respiratory disease, Alzheimer’s, HIV and more, at its HQ in Dublin.
Serving as a global process and manufacturing research epicentre, The Medicine Accelerator Campus represents one of the most disruptive businesses in pharmaceutical development, digitalization and manufacturing. At its core, this disruption will be facilitated by three interwoven strategic elements:
Best-in-class Science: Advancing the boundaries of pharmaceutical process research and development through a world class team of scientific experts.
First-in-class Digital: Accelerating medicine development and manufacturing outcomes through the application of our state-of-the-art digital technologies and Artificial Intelligence.
Science-First Manufacturing: Driving manufacturing outcomes through industry-first scientific and digitalization breakthroughs.